Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial

Background Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG trial, we showed that homocysteine‐lowering treatment with B vitamins slows the rate of brain atrophy in mild cognitive impairment (MCI). Here we report the effect of B vitamins on cognitive and...

Full description

Saved in:
Bibliographic Details
Published in:International journal of geriatric psychiatry Vol. 27; no. 6; pp. 592 - 600
Main Authors: de Jager, Celeste A., Oulhaj, Abderrahim, Jacoby, Robin, Refsum, Helga, Smith, A. David
Format: Journal Article
Language:English
Published: Chichester, UK John Wiley & Sons, Ltd 01.06.2012
Psychology Press
Wiley Subscription Services, Inc
Subjects:
ISSN:0885-6230, 1099-1166, 1099-1166
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first